Situated among one of the world’s largest neuroscience communities, the Massachusetts General Hospital provides an array of neurotherapeutic treatments for our varied patient populations. Experts from the Department of Neurology, Department of Neurosurgery, Department of Psychiatry, the Athinoula A. Martinos Center for Biomedical Imaging and beyond develop and implement neurotherapeutics and associated diagnostics for individuals with complex brain disorders affecting cognition, behavior, emotion, sensory and motor functioning.
The ALS Multidisciplinary Clinic in the Healey Center for ALS at Mass General provides personalized care and access to the latest treatments and research opportunities for people with ALS, commonly known as Lou Gehrig’s disease.
The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital is dedicated to finding new treatments for bipolar disorder, providing high-quality clinical care and educating our colleagues, our patients, their families and the community about this disorder.
The Mass General Epilepsy Service offers diagnosis, treatment, and consultations for seizure disorders, including surgical evaluations, and specialized care for first seizure events.
The Intravenous (IV) Ketamine Clinic for Depression at Massachusetts General Hospital offers patients and their professional providers access to ketamine treatment for severe and refractory depression. Movement Disorders Unit
The Movement Disorders Unit at Mass General sees patients from around the world for everything from the most common to the rarest of movement disorders.
For several decades the Massachusetts General Hospital Department of Neurosurgery and Department of Neurology have led in patient care for those with Parkinson's disease and advancing clinical research to develop new treatments with the hope of creating a cure.
The MassGeneral Hospital for Children Epilepsy Surgery Program provides surgical evaluation and treatment for pediatric patients whose epilepsy cannot be managed with medical therapy or those for whom surgery is the best option overall.
The mission of the Pediatric Psychopharmacology and Adult ADHD Program at Massachusetts General Hospital is to advance the well-being of children and families afflicted with mental illness through research, education and clinical care.
The TMS Clinical Service at Massachusetts General Hospital provides non-invasive treatment for patients with major depressive disorder who are unable to find relief through antidepressant medications or psychotherapy.
The ATRC in the Department of Neurology at Massachusetts General Hospital serves as a molecular and anatomic neuropathology resource for the Boston neuroscience community.
Our lab, led by Bakhos Tannous, PhD, focuses on molecular imaging, gene transfer technologies and high throughput screening aiming at finding novel therapeutics against brain tumors.
The Microfluidics Core provides know-how and state-of-the-art facilities for investigators in nervous system development, function, and dysfunction, to measure, control, and perturb the cellular microenvironment at the scale comparable to cell size.
The Multiphoton Imaging Core is part of the Neurosciences Center at Massachusetts General Hospital. The technology of multiphoton microscopy allows imaging of visible light fluorophores.
The Neurotherapeutics Program at Massachusetts General Hospital encompasses the clinical, research and training activities related to device-based treatments for psychiatric disorders.
Our lab is focused on understanding neural repair mechanisms and outcomes after stroke in order to guide the development and clinical translation of novel neurotechnologies to optimize stroke recovery.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital will join the new ALS Collaborative Cohort program with a grant from Tambourine, Ben and Divya Silbermann’s philanthropy.
Mai Uchida, MD, shares her “My Why”—outlining her decision to get the COVID vaccine during her pregnancy. Dr. Uchida hopes that she can be of help to anyone struggling with a similar decision by sharing her thought process, her emotions as a mother and her expertise as a physician.
The HEALEY ALS Platform Trial team is launching a new webinar series to enable members of the ALS community to learn about the mechanism of action and science behind each of the drugs currently in testing in the Platform Trial.
I AM ALS and the Sean M. Healey and AMG Center for ALS have announced a new grant to provide expanded access to verdiperstat, one of the drugs being tested in the HEALEY ALS Platform Trial.
The MGH Immigrant Health Coalition will host its third annual Migration is Beautiful campaign from Dec. 14 through 18, as part of a nationwide movement to celebrate the resilience and courage of those who come the United States seeking better opportunities and lives.
1of
6
Advances in Motion Neuroscience
Read the latest research coming from our research programs and laboratories from Mass General Neuroscience.